Jill White Launches "Becoming Her Again," a Coaching Journey for Christian Women Over 40 Rebuilding Purpose and Confidence
The program offers a faith-rooted framework to help women rediscover their identity, confidence, and purpose during and after midlife transitions
NEW BRAUNFELS, Texas, June 12, 2025 /CNW/ -- Jill White, Certified Life and Business Coach, international speaker, and founder of Overflow Coaching, is proud to announce the launch of her new signature program, "Becoming Her Again", a 90-day transformational experience created for Christian women over 40 who feel disconnected from their identity and uncertain about what's next.
Launching on June 15, 2025, the program is designed to help midlife women navigate the emotional and spiritual impact of life transitions like empty nests, career shifts, divorce or widowhood. With a faith-based, purpose-driven approach, Becoming Her Again blends mindset coaching, identity work, and personal growth strategy to help participants rediscover who they are, renew their purpose, and rebuild confidence from the inside out so they can be successful as they enter their next season of life.
According to a recent Barna study, 73% of Christian women over 40 report feeling uncertain about their purpose in this stage of life, despite deep spiritual roots and a history of leadership in their homes, churches, and communities. "This program was born out of conversations with women who kept saying, 'I don't even recognize myself anymore,'" says Jill White. " Becoming Her Again gives them a place to remember who God created them to be and believe it's not too late to step into something beautiful with peace, purpose, and confidence again."
Through one-on-one guidance, community support, and biblically aligned tools, Jill helps women break free from identity loss and self-doubt to confidently embrace their next chapter. The coaching process combines almost four decades of experience in coaching and mentoring, education, and leadership with spiritually grounded insights, offering a path for lasting transformation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
PointClickCare Pledges $75,000 to the Senior Living CaRES Fund in Support of Education Grants for Senior Living Workers
Leading health tech company commemorates National Long-Term Care Day with three-year commitment aimed at strengthening and empowering Canada's senior living workforce TORONTO, June 13, 2025 /CNW/ -- PointClickCare, a leading health tech company helping providers deliver exceptional care, today announced a three-year philanthropic partnership with the Senior Living CaRES Fund. The company will contribute $25,000 annually — totaling $75,000 — to fund educational grants that support professional development for workers in long-term care and retirement communities across Canada. Founded in 2020, the Senior Living CaRES Fund has provided over $3 million in emergency financial assistance and educational grants to frontline workers. The fund recognizes the vital role senior living professionals play in caring for older adults and is committed to fostering a stronger, more resilient workforce. "At PointClickCare, we believe that investing in people is the most meaningful way to drive lasting impact," said Angeline Pleunis, Vice President, Workplace Experience & Social Impact at PointClickCare. "The individuals working in senior living communities play an essential role in the health and well-being of our aging population, and they deserve every opportunity to grow, thrive, and succeed in their careers. Our partnership with the Senior Living CaRES Fund reflects our deep commitment to supporting this incredible workforce through education and development." The COVID-19 pandemic highlighted significant challenges in long-term care and heavily burdened frontline staff. These workers showed, and continue to show, remarkable resilience and compassion, often making personal sacrifices. It's clear that investing in their education and development is essential. PointClickCare's support enhances access to continuing education and training, equipping staff to excel in their careers and improve care quality. "We are incredibly grateful for PointClickCare's generous commitment to the Senior Living CaRES Fund," said Rebecca Scott Rawn, Executive Director at Senior Living CaRES Fund. "Their support will directly empower frontline workers with access to education and professional development opportunities – tools that not only enhance individual careers but strengthen the quality of care for seniors across Canada. Together, we are investing in the champions who make compassionate care possible every day." On National Long-Term Care Day, PointClickCare and the Senior Living CaRES Fund are proud to honour the dedication of those working in senior living communities. Together, they are investing in a future where every senior living worker feels valued, supported, and empowered to make a lasting impact. To learn more about PointClickCare's award-winning culture and philanthropic programs, visit the website here. For more information on the Senior Living CaRES Fund, visit the website here. About PointClickCare PointClickCare is a leading health tech company with one simple mission: to help providers deliver exceptional care. With the largest long–term and post–acute care dataset, we power AI-driven healthcare to deliver intelligent transitions, insightful interventions, and improved financial performance. Enhanced by our marketplace of 400+ integrated partners and trusted by over 30,000 provider organizations and every major U.S. health plan, we're redefining healthcare, so it doesn't just survive — it thrives. About The Senior Living CaRES Fund Established in May 2020 by founding partners Chartwell Retirement Residences, Revera Inc., Extendicare, and Sienna Senior Living, the Senior Living CaRES Fund was created in recognition of the extraordinary efforts of senior living sector employees whose passion, commitment and resilience while caring for the most vulnerable is nothing short of heroic. Since its establishment, the Fund has assisted over 970 employees across the country, distributing more than $3.1 million in emergency financial aid and bursaries for education.
Cision Canada
5 hours ago
- Cision Canada
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /CNW/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Comparative Arms: MagicTouch SCB vs. Everolimus-Eluting Stent (EES) Patient Population: 1,832 patients with de-novo lesions in coronary arteries (vessel diameter >2.0 mm to ≤3.5 mm; lesion length ≤50 mm) Primary Endpoint: Target Lesion Failure at 12 months, non-inferiority design Follow-Up: Patients will be monitored for up to 60 months (5 years) Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to assess angiographic outcomes Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
Cision Canada
11 hours ago
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED Français
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
